Respiratory Syncytial Virus Consortium in Europe

RESCUE is funded by the Innovative Medicines Initiative Joint Undertaking, cofunded by the European Commission FP7 Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA), and aims to gather information on the scale of RSV infection in Europe and its economic impacts, using this information to design best practice guidelines for monitoring of RSV and to shape future vaccination programmes.

The consortium will also identify biological markers associated with severe RSV infection to aid in diagnosis and facilitate the development of new treatments and vaccines.

As a partner, Penta is contributing to health care systems data collection and leads activities around networking and linkage to Regulatory Authorities. In addition, through our collaboration with the Laboratory of Mass Spectrometry and Metabolomics, Department of Women’s and Children’s Health, University of Padova, Penta is supporting the metabolomic analysis for biomarkers discovery and analysis of complex biomarker data sets.

Go to website

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement Nº 116019. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Europe’s project RESCEU sheds new light on the fight against the Respiratory Syncytial Virus and its economic impact